Suncoast Sees AI as a Potential Growth Driver for McKesson
The investment manager says AI may eventually improve McKesson’s forecasting, logistics and administrative efficiency, adding to its growth over time.
Key takeaways
- Suncoast Equity Management said AI could add another layer to McKesson’s growth over time.
- The manager identified forecasting, logistics and administrative efficiency as potential areas of improvement.
Suncoast Equity Management said artificial intelligence could become another growth driver for McKesson, pointing to possible improvements in forecasting, logistics and administrative efficiency. The view appeared in the manager’s Q3 2026 investor letter.
The letter said McKesson continues to deliver mid-teens earnings growth and strong free cash flows. It attributed the results to factors including drug-volume growth, expansion in specialty pharmaceuticals and acquisitions.
Suncoast also said AI could potentially accelerate drug discovery and increase the number of complex therapies handled through McKesson’s distribution and specialty-care networks. The manager said the company’s share price had moved little year to date, despite what it described as strong growth, and expects stock returns to eventually follow profits.
This article was produced with the help of AI technology. Source: Yahoo Finance
